38956-34-2

Upstream product

• 94-45-1 2-Amino-6-ethoxybenzothiazole 
• 70-11-1 α-bromoacetophenone 
• 70066-70-5 5-ethoxybenzo[d]thiazol-2-amine 

Downstream Products

• 1334950-71-8 3-(pyrrolidinomethyl)-2-phenyl-7-ethoxyimidazo[2,1-b]benzothiazole 
• 1334950-66-1 3-(morpholinomethyl)-2-phenyl-7-ethoxyimidazo[2,1-b]benzothiazole 
• 1334950-67-2 3-(4-(2-pyridinyl)piperazinomethyl)-2-phenyl-7-ethoxyimidazo[2,1-b]benzothiazole 

Relevant academic research and scientific papers

Molecular interaction of novel benzothiazolyl triazolium analogues with calf thymus DNA and HSA-their biological investigation as potent antimicrobial agents

The binding behaviour between calf thymus DNA and synthesized benzothiazolyl triazolium derivatives as potent antimicrobial agents was explored by means of spectroscopic applications together with molecular docking study at the sub-domain IIA, binding sit

Imidazole benzothiazole ether compound, preparation method of pharmaceutically acceptable salt thereof and application

The invention relates to an imidazole benzothiazole ether compound, a preparation method of pharmaceutically acceptable salt thereof and application. The imidazole benzothiazole ether compound is shown in formulas I to III; the compound has certain activi

Azoalkyl ether imidazo[2,1-b]benzothiazoles as potentially antimicrobial agents with novel structural skeleton

A series of new azoalkyl ether imidazo[2,1-b]benzothiazoles were developed via a convenient synthetic procedure. The antimicrobial assays showed that a good number of the prepared derivatives exhibited significant inhibitory properties against most of the

Schiff base imidazo and benzothiazole compound as well as preparation method and application thereof

The invention relates to schiff base imidazo and benzothiazole compounds as well as a preparation method and application thereof. The compounds are of structures of formulae I to VII as shown in the description. The compounds have certain inhibition activ

Synthesis and biological evaluation of novel Mannich bases of 2-arylimidazo[2,1-b]benzothiazoles as potential anti-cancer agents

A new series of Mannich bases of 2-arylimidazo[2,1-b]benzothiazoles were synthesized and evaluated for their anti-cancer activity. These compounds showed better cytotoxicity activity with IC50 values ranging from 2.8 to 8.0 μM in HepG2, MCF-7 and HeLa cell lines. Further mechanism aspects responsible for the anti-cancer activity of two promising compounds 3c and 3f in HepG2 cell line were studied. Interestingly, 3c, 3f induced G2/M cell cycle arrest with down regulation of cyclin B and up regulation of Chk2 protein. Moreover, compounds 3c, 3f also showed the characteristic features of apoptosis such as enhancement in the levels of caspase-3. Treatments with compounds led to a decrease in levels of vital cell proliferation proteins such as Jun (C-Jun, JunB), p38 MAPK, p-JNK and PKCα. The compound 3f of the series could be considered as the potential lead for its development as a novel anti-cancer agent.